| | | | |
![LOGO](https://capedge.com/proxy/SC 13G/0001193125-22-048281/g285355rrd.jpg) | | | | Schedule 13G Template |
Page 3 of 5 Pages
Item 1(a) Name of issuer:
NexImmune, Inc.
Item 1(b) Address of issuer’s principal executive offices:
9119 Gaither Road, Gaithersburg, Maryland 20877
2(a) Name of person filing:
Louise F. Brady
2(b) Address or principal business office or, if none, residence:
300 N Greene Street, Suite 1750, Greensboro, North Carolina 27401
2(c) Citizenship:
United States of America
2(d) Title of class of securities:
Common Stock, $0.0001 par value per share
2(e) CUSIP No.:
65344D109
Item 3. If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);
(e) [ ] An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);
(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
(j) [ ] A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k) [ ] Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a) Amount beneficially owned: 1,563,124.